UCB S.A. Earnings Call Highlights BIMZELX-Led Surge

UCB S.A. Unsponsored ADR ((UCBJY)) has held its Q4 earnings call. Read on for the main highlights of the call.

UCB S.A. Unsponsored ADR’s latest earnings call struck an upbeat tone as management highlighted robust growth, sharply higher profitability, and accelerating pipeline progress. Executives balanced this optimism with caution on pricing headwinds, loss of exclusivity, and clinical risk, but argued that momentum in BIMZELX and other growth drivers more than offsets these challenges.

Revenue Surge Underpins Growth Narrative

UCB reported 2025 total revenues of €7.7 billion, up 26% year over year, or 29% at constant exchange rates, showcasing strong underlying demand. Net sales neared €7.4 billion, rising 32% and 35% at constant FX, positioning the company firmly in a high-growth bracket relative to many large-cap biotech peers.

Five Growth Engines More Than Double

The company’s five designated growth drivers delivered €3.3 billion in revenue during 2025, more than twice their contribution in the prior year and now a central pillar of the investment story. BIMZELX was the standout, accounting for over €2.2 billion of that total and validating the strategic pivot toward immunology and rare diseases.

BIMZELX Builds Global Commercial Scale

BIMZELX continued its rapid ascent, with net sales exceeding €2.2 billion in 2025 and approvals now in more than 50 countries, treating over 116,000 patients. Management cited dynamic market share of about 30% in psoriasis, 20% in rheumatology, and 45% in hidradenitis suppurativa, with U.S. HS share climbing to roughly 32% from 25% in July.

Margins Expand As Profitability Steps Up

Profitability moved sharply higher, with adjusted gross profit reaching €6.1 billion, up 27%, and a gross margin of 79.2% as mix shifted to higher-value assets. Adjusted EBITDA jumped 79% to €2.6 billion, or 87% at constant FX, lifting the EBITDA margin by 10 percentage points to 34% and supporting a stronger long-term earnings profile.

EPS Jumps And Balance Sheet Delevered

Core EPS nearly doubled to €9.99, reflecting both revenue growth and operating leverage across the portfolio. Strong cash generation allowed UCB to fully deleverage its balance sheet, cutting net financial expenses to €126 million and giving the company more flexibility for R&D, capacity investments, or potential business development.

Regulatory Wins And Pipeline Progress

On the pipeline front, KYGEVVI secured U.S. approval and a positive CHMP opinion for TK2 deficiency, with a U.S. launch targeted for early 2026, adding a new rare-disease revenue stream. UCB also reported positive Phase II data and an FDA fast-track designation for the Alzheimer’s candidate bepranemab, while prioritizing galvokimig after two bispecifics in atopic dermatitis hit primary endpoints.

Clinical And Development Cadence Accelerates

Management emphasized a packed development calendar, including moving the BE BOLD psoriatic arthritis readout earlier into the first half of 2026, reflecting confidence in BIMZELX’s expansion potential. FINTEPLA is advancing into a Phase III program in Rett syndrome, while RYSTIGGO prepares to enter Phase III in ocular myasthenia gravis and galvokimig heads into COPD and bronchiectasis studies.

Big U.S. Manufacturing Bet For BIMZELX

UCB unveiled a major strategic manufacturing move, with a planned U.S. mammalian facility representing around $5 billion in direct and indirect investment. The site is designed to secure long-term BIMZELX supply and bolster the company’s U.S. industrial footprint, signaling management’s conviction in sustained demand for the franchise.

Broader Franchise And Partner Assets Add Depth

Beyond BIMZELX, partner asset EVENITY generated a net contribution of €632 million, up 32%, underlining the value of collaborations. RYSTIGGO and ZILBRYSQ together added more than €270 million in incremental net sales, while FINTEPLA grew 26% year on year to €427 million and treated more than 14,000 patients, and CIMZIA volumes rose 4% despite pricing headwinds.

ESG Scores Strengthen Investor Appeal

The group also highlighted progress on sustainability, noting an improved CDP climate change rating to A, signaling stronger climate-related disclosure and performance. UCB ranked number two among global biotech peers in Sustainalytics’ industry assessment, supporting the stock’s appeal for ESG-focused investors alongside its financial momentum.

Net Pricing And Gross-To-Net Pressures Build

Management warned that revenue growth is increasingly volume-driven, with net prices under pressure as U.S. access broadens and more prescriptions are rebated. A second-half 2025 true-up on BIMZELX gross-to-net equated to about 5% of total BIMZELX revenue, and similar dynamics are expected to weigh on net pricing even as prescription volumes climb.

Loss Of Exclusivity And Portfolio Headwinds

The epilepsy drug BRIVIACT has just lost U.S. exclusivity and faces European loss of exclusivity in August 2026, introducing another drag on the mature portfolio. UCB has factored this impact, along with a modest negative perimeter effect from a past asset disposal, into its 2026 guidance, framing it as manageable given growth elsewhere.

CIMZIA Feels Impact Of U.S. Pricing Reform

CIMZIA net sales fell 4% to €1.95 billion, though were flat at constant exchange rates, as U.S. pricing pressure offset volume growth. Management cited changes under the Inflation Reduction Act in Medicare Part D and a growing 340B effect as key drivers, underscoring how policy shifts are reshaping returns across established immunology brands.

Trial Noise And Competitive Pressures In Immunology

Executives acknowledged rising industry-wide trial noise and recruitment challenges in immunology and inflammation, including higher placebo responses and difficulty enrolling biologically naïve moderate-to-severe patients. These issues, combined with intense competition in Alzheimer’s and respiratory and dermatology arenas, led UCB to deprioritize donzakimig in favor of the more promising galvokimig.

One-Off Costs Reflect Portfolio Reshaping

Reported results included €111 million of one-off costs linked to contractual commitments on a non-core asset, highlighting ongoing portfolio pruning. While a €315 million asset sale benefited other operating income, management framed both items as non-recurring noise rather than a shift in the underlying earnings trajectory.

Tax Rate Set To Rise In 2026

UCB’s effective tax rate was a favorable 14% in 2025, partly thanks to research and development incentives, boosting net profit. The company now expects its tax rate to step up to around 20% in 2026, a headwind that will temper bottom-line growth even as operating metrics continue to improve.

High-Risk Assets Still Need De-Risking

Despite promising early data, high-profile programs such as bepranemab in Alzheimer’s disease remain in inherently high-risk categories. Management signaled a pragmatic stance, expressing openness to partnerships that could share clinical and regulatory risk while preserving upside if the science ultimately delivers.

Guidance Signals Continued Growth And Margin Upside

Management guided for 2026 revenue growth in the high-single-digit to low-double-digit range at constant exchange rates, building on 2025’s €7.7 billion revenue base. Adjusted EBITDA is expected to grow from an underlying €2.4 billion base at a high-teens to high-20s percentage rate at constant exchange, driven by the five growth drivers, margin expansion, disciplined G&A, and despite higher R&D spend and a rising tax rate.

UCB’s earnings call painted the picture of a company transitioning successfully into a higher-growth, higher-margin phase, anchored by BIMZELX and a diversified next-wave pipeline. While investors must watch pricing pressure, loss of exclusivity, and trial risk closely, the combination of strong balance sheet, manufacturing investment, and robust guidance leaves the growth story intact and still gathering pace.